N/A N=28 Surveillance of Humira in Korean JIA Patients
Polyarticular Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events — 6; 1; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
Chronic Plantar Fasciitis
Primary: Responders Rate at Week 6 (Pain While Moving) — 25.0; 5.0 Percentage of participants — p==0.182
N/A N=58 A Retrospective Analysis of the Effects of Red Light Therapy on Body Contouring
Obesity
Primary: Fat Reduction in Treatment Zone as Measured in Inches Lost — 3.5 inch
N/A N=240 POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
Phase 2 N=53 Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
Pancreatic Adenocarcinoma
Primary: Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 subjects
N/A N=12 Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform
Diabetes Mellitus, Type 1
Primary: Percent of Sensor Glucose Readings Between 70-180 mg/dL — 46.9; 73.1 percentage of time in range
N/A N=159 Genetically Guided Statin Therapy
Hypercholesterolemia · Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Primary: Morisky Medication Adherence Scale (MMAS) Score — 6.8; 6.9; 6.8; 7.1 units on a scale — p=0.96
Phase 2 N=26 Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Effect of Drug Combination on Multiple Myeloma — 2; 9; 9; 5 participants
Phase 2 N=54 A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma
Asthma · Efficacy · Safety
Primary: Efficacy of AZD7594 by Assessment of the Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 15 — 0.08639; 0.05948; 0.1355; 0.05948…
Phase 3 N=391 A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
Forehead Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
Phase 4 N=104 Relapse Prevention With Varenicline
Recurrence · Smoking Cessation · Substance-Related Disorders
Primary: Days to Relapse — 9.1; 16.4 days
Phase 2 N=27 Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Patients Experiencing a Dose-limiting Toxicity (Phase I) — 3; 0 Participants
Phase 2 N=61 Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: Bone Mineral Density BMD of the Total Hip as Assessed by DXA. — 0.66; 0.63; 0.64; 0.65 g/cm^2 — p=0.84
N/A N=1,100 Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Patients
Uterine Cervical Neoplasms
Primary: Proportion of Patients Who Receive a Pap Test at End of Follow up — 44; 50; 53; 59 Participants
N/A N=50 BioFiber Scaffold Post-Market Observational Study
Full Thickness Rotator Cuff Tear
Primary: Number of Participants With Device Associated Adverse Events — 4 Participants